5 amino 1mq human trials reviews 5-Amino-1MQ 5mg 5-AMINO 1MQ - 10mg Vial

Preclinical research has examined AHK-Cu in fibroblast and dermal cell culture models for its effects on collagen and glycosaminoglycan synthesis via TGF- pathway interaction

AHK-Cu is structurally related to other copper peptide systems, but differs by its alanine-histidine-lysine sequence, which may contribute to distinct receptor interactions and experimental behavior compared with glycine-based copper tripeptides

+ - AOD-9604 generally takes 4 to 12 weeks of consistent use to produce noticeable fat-loss results

The research summary below describes published scientific literature

The compound has never received market authorization in Canada or anywhere else, and Metabolic Pharmaceuticals terminated clinical development in 2007 after the Phase IIb obesity trial failed

Important Notice This product is intended for laboratory research use only